Clinical Trial Update: A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP)) [Phase 3]

View source ↗

Summary

Phase 3 study comparing fluticasone furoate/vilanterol inhalation powder versus salmeterol/fluticasone propionate in chronic obstructive pulmonary disease; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone furoate/vilanterol inhalation powder (fluticasone furoate/vilanterol)
• Salmeterol/Fluticasone Propionate Inhalation Powder (salmeterol/fluticasone propionate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2013-07-30